The use of GSIs for cancers is primarily based on the premise that GSIs act by inhibiting the cleavage of γ-secretase, which result in blocking NOTCH1 signaling; modulation of the NOTCH pathway increases glioma cell sensitivity to temozolomide [83]. The gene discussed is NOTCH1; the disease is glioma.